U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 2I.Pt
Molecular Weight 448.893
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PLATINOUS IODIDE

SMILES

[I-].[I-].[Pt++]

InChI

InChIKey=ZXDJCKVQKCNWEI-UHFFFAOYSA-L
InChI=1S/2HI.Pt/h2*1H;/q;;+2/p-2

HIDE SMILES / InChI

Molecular Formula HI
Molecular Weight 127.91241
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula Pt
Molecular Weight 195.084
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.drugbank.ca/drugs/DB00515 | https://www.ncbi.nlm.nih.gov/pubmed/27736024 | https://www.ncbi.nlm.nih.gov/pubmed/25159039

Platinous chloride is used as a catalyst in organic synthesis. The salt is insoluble in water.

CNS Activity

Curator's Comment: With the injection of cisplatin into mice 3 h after the LPS treatment, platinum was detected in the CCR during the 7 days after the injection, while platinum was not detected in the CCR of cisplatin-injected mice without LPS pretreatment and of mice simultaneous treated with cisplatin and LPS.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: CHEMBL2311221
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
CISPLATIN

Approved Use

Cisplatin injection is indicated as therapy to be employed as follows: Metastatic Testicular Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. Metastatic Ovarian Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of Cisplatin injection and cyclophosphamide. Cisplatin injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received Cisplatin injection therapy. Advanced Bladder Cancer Cisplatin injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy.

Launch Date

1978
Primary
CISPLATIN

Approved Use

Cisplatin injection is indicated as therapy to be employed as follows: Metastatic Testicular Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. Metastatic Ovarian Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of Cisplatin injection and cyclophosphamide. Cisplatin injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received Cisplatin injection therapy. Advanced Bladder Cancer Cisplatin injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy.

Launch Date

1978
Primary
CISPLATIN

Approved Use

Cisplatin injection is indicated as therapy to be employed as follows: Metastatic Testicular Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. Metastatic Ovarian Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of Cisplatin injection and cyclophosphamide. Cisplatin injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received Cisplatin injection therapy. Advanced Bladder Cancer Cisplatin injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy.

Launch Date

1978
Primary
CISPLATIN

Approved Use

Cisplatin injection is indicated as therapy to be employed as follows: Metastatic Testicular Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. Metastatic Ovarian Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of Cisplatin injection and cyclophosphamide. Cisplatin injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received Cisplatin injection therapy. Advanced Bladder Cancer Cisplatin injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy.

Launch Date

1978
PubMed

PubMed

TitleDatePubMed
Retrospective Analysis of the Risk Factors for Grade IV Neutropenia in Oesophageal Cancer Patients Treated with a Docetaxel, Cisplatin, and 5-Fluorouracil Regimen.
2017
Synthesis of tetracyclic chromenones via platinum(II) chloride catalysed cascade cyclization of enediyne-enones.
2014-02-28
Platinum-catalyzed one-pot alkenylation of aldehydes using alkynes and triethylsilane: dual catalysis by platinum(II) chloride.
2013-11-01
Platinum(II) chloride-catalyzed stereoselective domino enyne isomerization/Diels-Alder reaction.
2010-11-19
Patents

Patents

Sample Use Guides

Metastatic Testicular Tumors The usual Cisplatin Injection dose for the treatment of testicular cancer in combination with other approved chemotherapeutic agents is 20 mg/m2 IV daily for 5 days per cycle. Metastatic Ovarian Tumors The usual Cisplatin Injection dose for the treatment of metastatic ovarian tumors in combination with cyclophosphamide is 75 to 100 mg/m2 IV per cycle once every four weeks Advanced Bladder Cancer Cisplatin Injection should be administered as a single agent at a dose of 50 to 70 mg/m2 IV per cycle once every 3 to 4 weeks depending on the extent of prior exposure to radiation therapy and/or prior chemotherapy. All Patients Pretreatment hydration with 1 to 2 liters of fluid infused for 8 to 12 hours prior to a Cisplatin Injection dose is recommended. The drug is then diluted in 2 liters of 5% Dextrose in 1/2 or 1/3 normal saline containing 37.5 g of mannitol, and infused over a 6- to 8-hour period. If diluted solution is not to be used within 6 hours, protect solution from light. Do not dilute Cisplatin Injection in just 5% Dextrose Injection. Adequate hydration and urinary output must be maintained during the following 24 hours. A repeat course of Cisplatin Injection should not be given until the serum creatinine is below 1.5 mg/100 mL, and/or the BUN is below 25 mg/100 mL. A repeat course should not be given until circulating blood elements are at an acceptable level
Route of Administration: Intravenous
Human ovarian carcinoma cells A2780 and cisplatin resistant SKOV3 were routinely cultured in RPMI 1640 medium supplemented with 10% heat-inactivated FCS, 2 mM L-glutamine, 100mg/ml penicillin and 50mg/ml streptomycin. The effect of SFN (sulforaphane), cisPt (cisplatin) or their combination on the survival of cells was determined by MTT assay. The cells were seeded at 1–2 10^3 cell density in 96-well culture plates. Each dose of tested compounds (added in the volume of 50ml) was tested in triplicate or quadruplicate. After 72 h, the cells were incubated with 50ml of MTT (1 mg/ml) and left in the dark at 37 C for an additional 4 h. Thereafter, the medium was removed, the formazan crystals were dissolved in 200ml of DMSO, and the absorbance was measured at 540 and 690 nm in xMarkTM Microplate Spectrophotometer (Bio-Rad Laboratories, Inc.).
Substance Class Chemical
Created
by admin
on Mon Mar 31 22:43:41 GMT 2025
Edited
by admin
on Mon Mar 31 22:43:41 GMT 2025
Record UNII
SMK137T046
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PLATINOUS IODIDE
MI  
Common Name English
PLATINOUS IODIDE [MI]
Preferred Name English
PLATINUM DIIODIDE
Systematic Name English
PLATINUM IODIDE (PTI2)
Common Name English
PLATINUM(II) IODIDE
Systematic Name English
Code System Code Type Description
EPA CompTox
DTXSID50999091
Created by admin on Mon Mar 31 22:43:41 GMT 2025 , Edited by admin on Mon Mar 31 22:43:41 GMT 2025
PRIMARY
PUBCHEM
82252
Created by admin on Mon Mar 31 22:43:41 GMT 2025 , Edited by admin on Mon Mar 31 22:43:41 GMT 2025
PRIMARY
MERCK INDEX
m408
Created by admin on Mon Mar 31 22:43:41 GMT 2025 , Edited by admin on Mon Mar 31 22:43:41 GMT 2025
PRIMARY Merck Index
FDA UNII
SMK137T046
Created by admin on Mon Mar 31 22:43:41 GMT 2025 , Edited by admin on Mon Mar 31 22:43:41 GMT 2025
PRIMARY
ECHA (EC/EINECS)
232-204-2
Created by admin on Mon Mar 31 22:43:41 GMT 2025 , Edited by admin on Mon Mar 31 22:43:41 GMT 2025
PRIMARY
CAS
7790-39-8
Created by admin on Mon Mar 31 22:43:41 GMT 2025 , Edited by admin on Mon Mar 31 22:43:41 GMT 2025
PRIMARY